IL298678A - Modified semaphorin 3a, compositions comprising the same and uses thereof - Google Patents

Modified semaphorin 3a, compositions comprising the same and uses thereof

Info

Publication number
IL298678A
IL298678A IL298678A IL29867822A IL298678A IL 298678 A IL298678 A IL 298678A IL 298678 A IL298678 A IL 298678A IL 29867822 A IL29867822 A IL 29867822A IL 298678 A IL298678 A IL 298678A
Authority
IL
Israel
Prior art keywords
modified
sema3a
semaphorin
polypeptide
cells
Prior art date
Application number
IL298678A
Other languages
English (en)
Hebrew (he)
Original Assignee
Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel
Technion Res & Dev Foundation
The Chancellor Masters And Scholars Of The Univ Of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel, Technion Res & Dev Foundation, The Chancellor Masters And Scholars Of The Univ Of Oxford filed Critical Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel
Publication of IL298678A publication Critical patent/IL298678A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
IL298678A 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof IL298678A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063034476P 2020-06-04 2020-06-04
PCT/IL2021/050660 WO2021245670A1 (en) 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof

Publications (1)

Publication Number Publication Date
IL298678A true IL298678A (en) 2023-01-01

Family

ID=78830160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298678A IL298678A (en) 2020-06-04 2021-06-03 Modified semaphorin 3a, compositions comprising the same and uses thereof

Country Status (8)

Country Link
US (1) US20230272020A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161659A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532415A (cg-RX-API-DMAC7.html)
CN (1) CN115916351A (cg-RX-API-DMAC7.html)
AU (1) AU2021284697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185618A1 (cg-RX-API-DMAC7.html)
IL (1) IL298678A (cg-RX-API-DMAC7.html)
WO (1) WO2021245670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2497498A4 (en) * 2009-11-05 2013-04-17 Univ Osaka THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2014199364A1 (en) * 2013-06-13 2014-12-18 Bnai Zion Medical Center Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
AU2015311563B2 (en) * 2014-09-05 2019-11-28 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation
EP3262064A1 (en) * 2015-02-23 2018-01-03 Seagull Therapeutics SAS Non-natural semaphorins 3 and their medical use

Also Published As

Publication number Publication date
EP4161659A4 (en) 2024-03-06
WO2021245670A1 (en) 2021-12-09
EP4161659A1 (en) 2023-04-12
CN115916351A (zh) 2023-04-04
US20230272020A1 (en) 2023-08-31
CA3185618A1 (en) 2021-12-09
JP2023532415A (ja) 2023-07-28
AU2021284697A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
KR102302392B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
CN106659757B (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
CN111615396A (zh) 白介素-2的部分激动剂
CN110357953B (zh) 识别人巨细胞病毒pp65抗原的TCR
WO2001019999A1 (en) A GENE ENCODING A NOVEL THREONYL-tRNA SYNTHETASE, ITS USES AND THE PREPARING METHODS
US20250270272A1 (en) Methods of treating multiple sclerosis using autologous t cells
EP4310188A1 (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
EP1019502A2 (en) Human orphan receptor ntr-1
EP4010006B1 (en) Hla-dr/cii peptide complexes for treating arthritis
US20190000921A1 (en) Semaphorin 3a for treatment and prognosis of systemic lupus erythematosus
US20230272020A1 (en) Modified semaphorin 3a, compositions comprising the same and uses thereof
Daub et al. Expression of members of the S100 Ca2+-binding protein family in guinea-pig smooth muscle
KR20240128579A (ko) Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN115141268B (zh) 抗炎cd209多肽片段及其抗脂肪性肝病炎症的应用
US9943567B2 (en) Method for treating arthritis using IK factor or nucleic acid encoding IK factor
CN120019146A (zh) 通用t细胞和组合物及它们的使用方法
AU6176696A (en) Interleukin-1 receptor-associated protein kinase and assays
EP2032601B1 (en) Peptides regulating the surface expression of the t cell receptor
CN112538108B (zh) 高亲和pvr突变体
WO2001038371A1 (en) A NOVEL POLYPEPTIDE-HUMAN GLUTAMATE tRNA SYNTHETASE 58 AND THE POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE
EP4667486A1 (en) Composition comprising cd38 or fragment thereof for treating autoimmune diseases
WO2008118100A1 (en) Method of enhancing migration of neural precursor cells
US6908765B1 (en) Polypeptide—human SR splicing factor 52 and a polynucleotide encoding the same
HK40103877A (en) Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
US20260041789A1 (en) Gene therapy DNA vector based on gene therapy DNA vector GDTT1.8NAS12 carrying the therapeutic gene selected from the group of DDC, IL10, IL13, IFNB1, TNFRSF4, TNFSF10, BCL2, HGF, and IL-2 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain JM110-NAS/GDTT1.8NAS12-DDC, or Escherichia coli strain JM110-NAS/GDTT1.8NAS12-IL10, or Escherichia coli strain JM110-NAS/GDTT1.8NAS12-IL13, or Escherichia coli strain JM110-NAS/GDTT1.